Complement Glomerulopathy

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-05-02
Clinical Trial Update: Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) [Phase 2]
Phase 2 study evaluating safety and tolerability of BCX9930 in complement-mediated kidney diseases was terminated; results have been posted.